Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC

Condition:   EGFR Positive Non-Small Cell Lung Cancer,Adenocarcinoma Intervention:   Drug: Icotinib combined dihydroaremisinin Sponsors:   Beijing Cancer Hospital;   Betta Pharmaceuticals Co.,Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials